ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1956

Characterizing Arthritis Related to Immune Checkpoint Inhibitors Using Synovial Fluid and Matched Blood

Mazen Nasrallah1, Molly Thomas 2, Kasidet Manakongtreecheep 2, Daniel Zlotoff 2, Aleigha Lawless 2, Hellen Giang 2, Sara Schoenfeld 2, Ryan Sullivan 2, Genevieve Boland 2, Kerry Reynolds 2, Minna Kohler 2, Andrew Luster 2 and Alexandra-Chloé Villani 2, 1Massachusetts General Hospital, Boston, 2MGH, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: arthritis and genomics, Immunotherapy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Monoclonal antibodies against CTLA-4 and PD-1 have revolutionized the field of immuno-oncology over the past decade. These therapies however are limited by immune related adverse events (irAEs) that can affect nearly every organ system. Inflammatory arthritis (irIA) is a common well-recognized irAE, but with a poorly understood pathophysiology that results in limited targeted treatments. Mechanistic insight into disease pathogenesis has been hampered by the lack of animal models, as mice treated with these drugs do not develop significant irAEs. We thus designed a translational study using human samples focused on identifying distinct cells types, and critical signaling pathways involved in promoting irIA.

Methods: We have established a specialty clinic that provides comprehensive clinical evaluation and long-term follow up of patients with suspected rheumatological irAEs. This clinic also enables serial sample collection of synovial fluid and matched blood samples at the time of the patient’s first rheumatologic assessment and, when possible, serially before and after the initiation of immunosuppressive therapy. To define distinct cell populations that might be driving irIA pathogenesis and could be used as a diagnostic marker, we leveraged 10X Genomics droplet-based single-cell RNA-sequencing strategies that do not require an a prioriknowledge of the specific cell populations or signaling components involved. Single-cell TCR analysis was performed in parallel on the same samples using the VDJ enrichment strategy.

Results: Approximately, 25,000 single cells from the synovial fluid of 5 patients with different irIA clinical phenotypes were analyzed. Findings shows that synovial fluid is highly heterogenous in composition and includes diverse populations of myeloid and dendritic cells in high proportions. Furthermore, distinct CD8+ cytotoxic T cells across disease phenotypes were expanded. Paralleled single T cell receptor analyses identified diverse clonotypes within these expanded lymphocyte subsets, as well as clonotypic expansion within specific cytotoxic CD8+ populations across patients.

Conclusion: Our systems-level approach provides a better understanding of the biological basis of irIA. Importantly, because irIA provides a model to study mechanisms of immune-tolerance, we believe that our translational effort also represents a unique opportunity to study proximate events leading to autoimmunity in humans.


Disclosure: M. Nasrallah, None; M. Thomas, None; K. Manakongtreecheep, None; D. Zlotoff, None; A. Lawless, None; H. Giang, None; S. Schoenfeld, None; R. Sullivan, None; G. Boland, None; K. Reynolds, None; M. Kohler, Horizon pharma, 5, Springer, 7; A. Luster, None; A. Villani, None.

To cite this abstract in AMA style:

Nasrallah M, Thomas M, Manakongtreecheep K, Zlotoff D, Lawless A, Giang H, Schoenfeld S, Sullivan R, Boland G, Reynolds K, Kohler M, Luster A, Villani A. Characterizing Arthritis Related to Immune Checkpoint Inhibitors Using Synovial Fluid and Matched Blood [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/characterizing-arthritis-related-to-immune-checkpoint-inhibitors-using-synovial-fluid-and-matched-blood/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizing-arthritis-related-to-immune-checkpoint-inhibitors-using-synovial-fluid-and-matched-blood/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology